. Author manuscript; available in PMC: 2018 Sep 15.

Published in final edited form as: Biochem Pharmacol. 2017 Apr 27;140:8–15. doi: 10.1016/j.bcp.2017.04.027

Table 2.

Ongoing clinical trials designed to evaluate therapies based on furin inhibition.

Clinical trial	PC targeted	Target	Phase	NCT number
Bi: shRNA-Furin GMCSF	Furin (PCSK-3)	Ewin Sarcoma Non small lung cancer Liver cancer	I	01061840
FANG™ vaccine + Carboplatinum	Furin (PCSK-3)	Stage III and stage IV Ovarian cancer	II	01867086
FANG™ vaccine + Bevacizumab	Furin (PCSK-3)	Stage III and stage IV Ovarian cancer	II	0155145
FANG™ vaccine	Furin (PCSK-3)	Advanced melanoma	II	01453361
VIGIL + atezolizumab	Furin (PCSK-3)	Gynecological cancers	II	03073525